5 Oral selective tyrosine kinase 2 (TYK2) inhibition with BMS-986165 in patients with systemic lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study (PAISLEY)

MLA

Subhashis Banerjee, et al. “5 Oral Selective Tyrosine Kinase 2 (TYK2) Inhibition with BMS-986165 in Patients with Systemic Lupus Erythematosus: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study (PAISLEY).” Abstracts, Apr. 2019. EBSCOhost, https://doi.org/10.1136/lupus-2019-lsm.5.

APA

Subhashis Banerjee, Shalabh Singhal, John Throup, Vaishali Shah, Coby Hobar, Chris Crater, Joan T. Merrill, & Hoang Nguyen. (2019). 5 Oral selective tyrosine kinase 2 (TYK2) inhibition with BMS-986165 in patients with systemic lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study (PAISLEY). Abstracts. https://doi.org/10.1136/lupus-2019-lsm.5

Chicago

Subhashis Banerjee, Shalabh Singhal, John Throup, Vaishali Shah, Coby Hobar, Chris Crater, Joan T. Merrill, and Hoang Nguyen. 2019. “5 Oral Selective Tyrosine Kinase 2 (TYK2) Inhibition with BMS-986165 in Patients with Systemic Lupus Erythematosus: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study (PAISLEY).” Abstracts, April. doi:10.1136/lupus-2019-lsm.5.